Archiv
Archiv anzeigen:
bis


Resection of Cavity Shave Margins in Breast Conserving Surgery

Henry Mark Kuerer, MD, PhD, FACS reviewing Dupont E et al. Ann Surg 2019 Jul 8

Resection of additional tissue around the tumor cavity significantly reduces the need to return to surgery for margin control.


PET-Adapted Treatment for Hodgkin Lymphoma

Michael E. Williams, MD, ScM reviewing Barrington SF et al. J Clin Oncol 2019 Jul 10

The highest PET score following three cycles of induction chemotherapy was associated with poor outcomes in patients with early-stage disease.


Incidental Pulmonary Embolism in Cancer Patients

Brady L. Stein, MD, MHS reviewing Kraaijpoel N et al. J Clin Oncol 2019 Jul 10

Patients with incidental PE, including those with subsegmental involvement, had increased recurrence rates, despite treatment.


Another Antibody Drug Conjugate for Breast Cancer?

William J. Gradishar, MD reviewing Banerji U et al. Lancet Oncol 2019 Jun 27

In a phase I study, trastuzumab duocarmazine demonstrated antitumor activity with manageable toxicity in HER2-low breast cancers and other solid tumors.


Frontline Daratumumab for Transplant-Eligible Myeloma Patients

Michael E. Williams, MD, ScM reviewing Moreau P et al. Lancet 2019 Jul 6, Hofmeister CC et al. Lancet 2019 Jul 6

Outcomes were improved when daratumumab was combined with induction therapy prior to stem-cell transplant consolidation.


Venetoclax plus Obinutuzumab for Chronic Lymphocytic Leukemia

Michael E. Williams, MD, ScM reviewing Fischer K et al. N Engl J Med 2019 Jun 6

Outcomes were improved compared with standard chlorambucil plus obinutuzumab in previously untreated CLL patients with coexisting conditions.


Frontline Immunotherapy for Myeloma

Michael E. Williams, MD, ScM reviewing Facon T et al. N Engl J Med 2019 May 30

Daratumumab added to lenalidomide-plus-dexamethasone improved outcomes in newly diagnosed patients.


Ibrutinib plus Venetoclax for Chronic Lymphocytic Leukemia

Michael E. Williams, MD, ScM reviewing Jain N et al. N Engl J Med 2019 May 30

The combination therapy provided a high remission rate in previously untreated older and high-risk patients.


Fractionated Radiotherapy for Prostate Cancer: Current Status

Robert Dreicer, MD, MS, MACP, FASCO reviewing Widmark A et al. Lancet 2019 Jun 18, Catton C and Lukka H. Lancet 2019 Jun 18

An ultra-hypofractionated approach was found noninferior to conventional hypofractionation but was accompanied by more urinary-tract and bowel symptoms.


Docetaxel Fails to Improve Survival as Part of First-Line Chemotherapy in Gastric Cancer

David H. Ilson, MD, PhD reviewing Yamada Y et al. Lancet Gastroenterol Hepatol 2019 Jul

Cisplatin and S-1 remain the standard, based on phase III trial results.


Archiv
Seite von 82
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

Do CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer?

William J. Gradishar, MD reviewing Turner NC et al. N Engl J Med 2018 Oct 20

Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.


Immunotherapy for Breast Cancer Has Arrived

William J. Gradishar, MD reviewing Schmid P et al. N Engl J Med 2018 Oct 20

Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.


Brigatinib for ALK-Positive, Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Camidge DR et al. N Engl J Med 2018 Sep 25

Progression-free survival was prolonged with front-line brigatinib versus crizotinib.


Front-Line Therapy for Extensive-Stage, Small Cell Lung Cancer: A New Standard

Anne S. Tsao, MD reviewing Horn L et al. N Engl J Med 2018 Sep 25

Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.


A New Standard of Care for Squamous Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Paz-Ares L et al. N Engl J Med 2018 Sep 25

Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.


Durvalumab After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2018 Sep 25

Two-year overall survival was significantly improved with durvalumab versus placebo.


Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer

William J. Gradishar, MD reviewing Galimberti V et al. Lancet Oncol 2018 Sep 5

Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.


Olaparib plus Abiraterone for Advanced Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Clarke N et al. Lancet Oncol 2018 Jul

Progression-free survival was significantly longer with olaparib than with placebo.


Combination Immunotherapy for Metastatic Melanoma with Brain Metastases

Sunandana Chandra, MD, MS reviewing Tawbi HA et al. N Engl J Med 2018 Aug 23, Turajlic S and Larkin J. N Engl J Med 2018 Aug 23

Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.